IL-26 and Systemic Lupus Erythematosus

University Hospital, Strasbourg, France

Status: Terminated

Conditions: Diagnosis of Lupus According to ACR criteriaAgreement for the Blood Sampling

Study type: Observational

Funder types: Other

Identifiers

NCT01889641

5504

Details and patient eligibility

About

Treatment of multisystemic forms of lupus displays severe side effects and limited efficacy, underscoring the need to better dissection of the pathogenic mechanisms. Concordant with preliminary data, IL26 signaling could be impaired in systemic lupus. Moreover, IL 26 could be a marker of the disease activity and then a potential therapeutic target. In the present study, serum IL 26 level in lupus patients and control will be measured.

Enrollment: 23 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• diagnostic of Lupus according to ACR criteria ( four criteria are necessary)
• age > 18 years old

Exclusion criteria

• treatment by cyclophosphamide, rituximab, belimumab in the year before inclusion study

Trial design

23 participants in 2 patient groups

Patients with lupus

Description:

Patients with lupus (four levels of activity disease)

healthy volunteers

Description:

Subjects controls